J B Wong

Summary

Affiliation: Tufts-New England Medical Center
Country: USA

Publications

  1. ncbi request reprint Simulation of hepatitis C based on a mandatory reporting system
    Markus Sagmeister
    Division of Gastroenterology and Hepatology, University Hospital, Zurich, Switzerland
    Eur J Gastroenterol Hepatol 14:25-34. 2002
  2. ncbi request reprint Do the benefits of varicella vaccination outweigh the long-term risks? A decision-analytic model for policymakers and pediatricians
    Michael Rothberg
    Division of Clinical Decision Making, Informatics and Telemedicine, Department of Medicine, New England Medical Center, Tufts University School of Medicine, Boston, Massachusetts, USA
    Clin Infect Dis 34:885-94. 2002
  3. ncbi request reprint Should beta-blockers be given to patients with heart disease and peanut-induced anaphylaxis? A decision analysis
    John A TenBrook
    Division of Clinical Decision Making, Informatics, and Telemedicine, Department of Medicine, Tufts New England Medical Center, 750 Washington Street, Boston, MA 02111, USA
    J Allergy Clin Immunol 113:977-82. 2004
  4. ncbi request reprint Expanded criteria donor grafts for deceased donor liver transplantation under the MELD system: a decision analysis
    Manish G Amin
    Division of Gastroenterology and Institute for Clinical Research and Health Policy Studies, Tufts New England Medical Center, Tufts University School of Medicine, Boston, MA 02111, USA
    Liver Transpl 10:1468-75. 2004
  5. ncbi request reprint Cost-effectiveness of anti-tumor necrosis factor agents
    J B Wong
    Division of Clinical Decision Making, Department of Medicine, Tufts New England Medical Center, Tufts University School of Medicine, Boston, MA 02111, USA
    Clin Exp Rheumatol 22:S65-70. 2004
  6. ncbi request reprint Hepatitis C: cost of illness and considerations for the economic evaluation of antiviral therapies
    John B Wong
    Division of Clinical Decision Making, Department of Medicine, Tufts University School of Medicine, Tufts New England Medical Center, Tupper Research Institute, Boston, Massachusetts 02111, USA
    Pharmacoeconomics 24:661-72. 2006
  7. ncbi request reprint Pretreatment evaluation of chronic hepatitis C: risks, benefits, and costs
    J B Wong
    Department of Medicine, New England Medical Center, Tufts University School of Medicine, Boston, MA 02111, USA
    JAMA 280:2088-93. 1998
  8. pmc Estimating future hepatitis C morbidity, mortality, and costs in the United States
    J B Wong
    Department of Medicine, New England Medical Center, Tupper Research Institute, Tufts University School of Medicine, Boston, Mass, USA
    Am J Public Health 90:1562-9. 2000
  9. ncbi request reprint Patient-specific decisions about hormone replacement therapy in postmenopausal women
    N F Col
    Division of Clinical Decision Making, Informatics, and Telemedicine, Department of Medicine, New England Medical Center and Tufts University School of Medicine, Boston, Mass 02111, USA
    JAMA 277:1140-7. 1997
  10. ncbi request reprint Watchful waiting with periodic liver biopsy versus immediate empirical therapy for histologically mild chronic hepatitis C. A cost-effectiveness analysis
    J B Wong
    New England Medical Center, 750 Washington Street, Box 302, Boston, MA 02111, USA
    Ann Intern Med 133:665-75. 2000

Detail Information

Publications44

  1. ncbi request reprint Simulation of hepatitis C based on a mandatory reporting system
    Markus Sagmeister
    Division of Gastroenterology and Hepatology, University Hospital, Zurich, Switzerland
    Eur J Gastroenterol Hepatol 14:25-34. 2002
    ..Hepatitis C is a major cause of liver disease in European countries. We aimed to assess the current and future disease burden of hepatitis C...
  2. ncbi request reprint Do the benefits of varicella vaccination outweigh the long-term risks? A decision-analytic model for policymakers and pediatricians
    Michael Rothberg
    Division of Clinical Decision Making, Informatics and Telemedicine, Department of Medicine, New England Medical Center, Tufts University School of Medicine, Boston, Massachusetts, USA
    Clin Infect Dis 34:885-94. 2002
    ..Varicella vaccination of infants at age 12 months appears to be beneficial, even if the efficacy of the vaccine declines substantially...
  3. ncbi request reprint Should beta-blockers be given to patients with heart disease and peanut-induced anaphylaxis? A decision analysis
    John A TenBrook
    Division of Clinical Decision Making, Informatics, and Telemedicine, Department of Medicine, Tufts New England Medical Center, 750 Washington Street, Boston, MA 02111, USA
    J Allergy Clin Immunol 113:977-82. 2004
    ..Beta-blocker therapy postmyocardial infarction is generally recommended because it reduces mortality. However, beta-blockers may increase anaphylaxis mortality in the growing population of patients with peanut-induced anaphylaxis...
  4. ncbi request reprint Expanded criteria donor grafts for deceased donor liver transplantation under the MELD system: a decision analysis
    Manish G Amin
    Division of Gastroenterology and Institute for Clinical Research and Health Policy Studies, Tufts New England Medical Center, Tufts University School of Medicine, Boston, MA 02111, USA
    Liver Transpl 10:1468-75. 2004
    ..At less advanced MELD scores, the survival benefit depends on the risk of PGF associated with the ECD organ...
  5. ncbi request reprint Cost-effectiveness of anti-tumor necrosis factor agents
    J B Wong
    Division of Clinical Decision Making, Department of Medicine, Tufts New England Medical Center, Tufts University School of Medicine, Boston, MA 02111, USA
    Clin Exp Rheumatol 22:S65-70. 2004
    ..This paper reviews the disease burden of rheumatoid arthritis, costs of drug therapy, costs of rheumatoid arthritis and the economics and cost-effectiveness of anti-tumor necrosis factor antibody agents...
  6. ncbi request reprint Hepatitis C: cost of illness and considerations for the economic evaluation of antiviral therapies
    John B Wong
    Division of Clinical Decision Making, Department of Medicine, Tufts University School of Medicine, Tufts New England Medical Center, Tupper Research Institute, Boston, Massachusetts 02111, USA
    Pharmacoeconomics 24:661-72. 2006
    ....
  7. ncbi request reprint Pretreatment evaluation of chronic hepatitis C: risks, benefits, and costs
    J B Wong
    Department of Medicine, New England Medical Center, Tufts University School of Medicine, Boston, MA 02111, USA
    JAMA 280:2088-93. 1998
    ..Chronic hepatitis C (CHC) infection affects nearly 4 million people in the United States. Treatment with interferon alfa-2b has been limited by its cost and low likelihood of long-term response...
  8. pmc Estimating future hepatitis C morbidity, mortality, and costs in the United States
    J B Wong
    Department of Medicine, New England Medical Center, Tupper Research Institute, Tufts University School of Medicine, Boston, Mass, USA
    Am J Public Health 90:1562-9. 2000
    ..This study estimated future morbidity, mortality, and costs resulting from hepatitis C virus (HCV)...
  9. ncbi request reprint Patient-specific decisions about hormone replacement therapy in postmenopausal women
    N F Col
    Division of Clinical Decision Making, Informatics, and Telemedicine, Department of Medicine, New England Medical Center and Tufts University School of Medicine, Boston, Mass 02111, USA
    JAMA 277:1140-7. 1997
    ..To examine the effect of hormone replacement therapy on life expectancy in postmenopausal women with different risk profiles for heart disease, breast cancer, and hip fracture...
  10. ncbi request reprint Watchful waiting with periodic liver biopsy versus immediate empirical therapy for histologically mild chronic hepatitis C. A cost-effectiveness analysis
    J B Wong
    New England Medical Center, 750 Washington Street, Box 302, Boston, MA 02111, USA
    Ann Intern Med 133:665-75. 2000
    ..Not all patients with histologically mild chronic hepatitis C progress to cirrhosis...
  11. ncbi request reprint Long-term morbidity, mortality, and economics of rheumatoid arthritis
    J B Wong
    New England Medical Center, Boston, MA 02111, USA
    Arthritis Rheum 44:2746-9. 2001
    ..To estimate the morbidity, mortality, and lifetime costs of care for rheumatoid arthritis (RA)...
  12. ncbi request reprint Empirical anti-Candida therapy among selected patients in the intensive care unit: a cost-effectiveness analysis
    Yoav Golan
    Division of Geographic Medicine and Infectious Diseases, Tufts New England Medical Center, Boston, Massachusetts 02111, USA
    Ann Intern Med 143:857-69. 2005
    ..Mortality from invasive candidiasis is high. Low culture sensitivity and treatment delay contribute to increased mortality, but nonselective early therapy may result in excess costs and drug resistance...
  13. ncbi request reprint Meta-analysis: the effect of dietary counseling for weight loss
    Michael L Dansinger
    Tufts New England Medical Center, Boston, Massachusetts 02111, USA
    Ann Intern Med 147:41-50. 2007
    ..Dietary and lifestyle modification efforts are the primary treatments for people who are obese or overweight. The effect of dietary counseling on long-term weight change is unclear...
  14. ncbi request reprint Systematic review of outcomes after surgical management of venous disease incorporating subfascial endoscopic perforator surgery
    John A TenBrook
    Division of Clinical Decision Making, Department of Medicine, Tufts New England Medical Center, Boston, MA 02111, USA
    J Vasc Surg 39:583-9. 2004
    ..Patients in whom conservative therapies fail may improve after surgical treatment of superficial and perforating venous disease, but the degree of this benefit is uncertain...
  15. ncbi request reprint A geospatial analysis of emergency transport and inter-hospital transfer in ST-segment elevation myocardial infarction
    Thomas W Concannon
    Institute for Clinical Research and Health Policy Studies, Tufts New England Medical Center and Tufts University School of Medicine, Boston, Massachusetts, USA
    Am J Cardiol 101:69-74. 2008
    ..In conclusion, the selection of high-benefit patients for transport or transfer to PCI-capable hospitals can reduce mortality while minimizing major shifts in hospital patient volumes...
  16. pmc Cost effectiveness of peginterferon alpha-2b plus ribavirin versus interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C
    U Siebert
    Harvard Center for Risk Analysis, Harvard School of Public Health, Boston, MA, USA
    Gut 52:425-32. 2003
    ..Peginterferon alpha-2b plus ribavirin therapy in previously untreated patients with chronic hepatitis C yields the highest sustained virological response rates of any treatment strategy but is expensive...
  17. pmc Strategies for diagnosing and treating suspected acute bacterial sinusitis: a cost-effectiveness analysis
    E M Balk
    Evidence-based Practice Center, Division of Clinical Care Research, Tufts University School of Medicine, New England Medical Center, Boston, MA 02111, USA
    J Gen Intern Med 16:701-11. 2001
    ..Newer, expensive antibiotics are of limited value. Additional testing is not cost-effective. Further studies are needed to find an accurate,low-cost diagnostic test for acute bacterial sinusitis...
  18. ncbi request reprint Living-donor versus cadaveric liver transplantation for non-resectable small hepatocellular carcinoma and compensated cirrhosis: a decision analysis
    S J Cheng
    New England Medical Center, Tufts University School of Medicine, 750 Washington St, PO Box 302, Boston, MA 02111, USA
    Transplantation 72:861-8. 2001
    ..CONCLUSIONS: Living-donor liver transplantation should confer a substantial survival advantage for patients with compensated cirrhosis and non-resectable early stage hepatocellular carcinoma...
  19. ncbi request reprint Using competence network collaboration and decision-analytic modeling to assess the cost-effectiveness of interferon alpha-2b plus ribavirin as initial treatment of chronic hepatitis C in Germany
    Uwe Siebert
    Institute for Technology Assessment and Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, Mass, USA
    Eur J Health Econ 6:112-23. 2005
    ..Competence network collaboration and decision modeling provide a useful and efficient approach to combine evidence from international studies with country-specific parameters...
  20. ncbi request reprint Fitting nutrition into the medical model: the role of decision analytic cost-effectiveness techniques
    E M Ross
    Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University, Boston, Massachusetts 02111, USA
    Eur J Clin Nutr 53:S25-8. 1999
    ....
  21. ncbi request reprint Early infection in bone marrow transplantation: quantitative study of clinical factors that affect risk
    E A Engels
    Department of Medicine, Tupper Institute, New England Medical Center, Tufts University School of Medicine, Boston, Massachusetts, USA
    Clin Infect Dis 28:256-66. 1999
    ..Ciprofloxacin prophylaxis and particularly intravenous antibiotic therapy provide substantial protection at low neutrophil counts. These results can be used to model management strategies for transplant recipients...
  22. ncbi request reprint The economics of hepatitis C virus
    Bhavesh B Shah
    Division of Clinical Decision Making, Informatics, and Telemedicine, Tufts New England Medical Center, Tufts University School of Medicine, 750 Washington Street 302, Boston, MA 02111, USA
    Clin Liver Dis 10:717-34. 2006
    ..The global economic burden of this disease has yet to be fully realized. In this article the authors discuss the economic burden of hepatitis C, the economics of therapy, and the economics of its prevention and screening...
  23. ncbi request reprint Economics of chronic hepatitis B and hepatitis C
    Arathi Rajendra
    Division of Clinical Decision Making, Department of Medicine, Tufts New England Medical Center, Tufts University School of Medicine, 750 Washington Street, NEMC 302, Boston, MA 02111, USA
    J Hepatol 47:608-17. 2007
    ..This review should help clinicians understand economic issues regarding new drugs and answer questions about whether the clinical benefit provided by a medication justifies its expense...
  24. ncbi request reprint Using observational data to estimate prognosis: an example using a coronary artery disease registry
    E R DeLong
    Outcomes Research and Assessment Group, Duke Clinical Research Institute, Duke University, Department of Medicine, Biometry Division, Community and Family Medicine, 2400 Pratt Street, Durham, NC 27705, USA
    Stat Med 20:2505-32. 2001
    ..This paper discusses these issues and suggests strategies to deal with them. A proposed methodology is developed, applied and evaluated on a large observational database that has long-term follow-up on nearly 10 000 patients...
  25. ncbi request reprint Economic and clinical effects of evaluating rapid viral response to peginterferon alfa-2b plus ribavirin for the initial treatment of chronic hepatitis C
    John B Wong
    Division of Clinical Decision Making, Department of Medicine, Tupper Research Institute, Tufts New England Medical Center, Tufts University School of Medicine, Boston, Massachusetts 02111, USA
    Am J Gastroenterol 98:2354-62. 2003
    ..The aim of this study was to examine the economic and clinical effects of evaluating rapid viral response during antiviral therapy for treatment naive chronic hepatitis C patients...
  26. pmc All dysuria is local. A cost-effectiveness model for designing site-specific management algorithms
    Michael B Rothberg
    Division of Clinical Decision Making, Tufts New England Medical Center and Tufts University School of Medicine, Boston, MA 01199, USA
    J Gen Intern Med 19:433-43. 2004
    ..To determine the cost-effectiveness of management strategies for dysuria in different office settings...
  27. doi request reprint Interferon treatment in hemodialysis patients with chronic hepatitis C virus infection: a systematic review of the literature and meta-analysis of treatment efficacy and harms
    Craig E Gordon
    Division of Nephrology, Institute for Clinical Research and Health Policy Studies, Tufts New England Medical Center, Boston, MA 02111, USA
    Am J Kidney Dis 51:263-77. 2008
    ..We determined the efficacy and harms of interferon (IFN) and pegylated IFN (PEG-IFN) treatment of hemodialysis patients with chronic HCV infection and identified factors associated with these outcomes...
  28. pmc Interferon for hepatitis C virus in hemodialysis--an individual patient meta-analysis of factors associated with sustained virological response
    Craig E Gordon
    Division of Nephrology, Department of Medicine, Tufts Medical Center, Boston, Massachusetts, USA
    Clin J Am Soc Nephrol 4:1449-58. 2009
    ..The authors aimed to identify factors associated with SVR in hemodialysis patients through analysis of individual patient data obtained from systematic review of published literature...
  29. ncbi request reprint Is it influenza or anthrax? A decision analytic approach to the treatment of patients with influenza-like illnesses
    Andrew M Fine
    Division of Emergency Medicine, Children s Hospital Boston, Harvard Medical School, Boston, MA 02115, USA
    Ann Emerg Med 43:318-28. 2004
    ..We analyze the risks and benefits of alternative treatment strategies for non-septic-appearing febrile patients with influenza-like illnesses and possible exposure to anthrax...
  30. doi request reprint A cost-effectiveness analysis of subject recruitment strategies in the HIPAA era: results from a colorectal cancer screening adherence trial
    Paul C Schroy
    Department of Medicine, Boston University School of Medicine, Boston, MA 02118, USA
    Clin Trials 6:597-609. 2009
    ..Changes in regulatory standards that restrict use of identifiable health information can reduce patient recruitment to clinical trials and increase recruitment costs...
  31. ncbi request reprint Pharmacogenomics of hepatitis C and decision analysis: a glimpse into the future
    John B Wong
    Division of Clinical Decision Making, Department of Medicine, Tupper Research Institute, Tufts New England Medical Center, Tufts University School of Medicine, 750 Washington Street, Boston, MA 02111, USA
    Hepatology 36:252-4. 2002
  32. doi request reprint Comparative effectiveness research and the psychology of medical practice: the vicissitudes of knowledge implementation
    Jerome P Kassirer
    Division of Clinical Decision Making, Department of Medicine, Tufts Medical Center, Tufts University School of Medicine, Boston, Massachusetts, USA
    Pharmacoeconomics 28:899-903. 2010
    ..Taking the perspective of medical care providers, we consider many of the psychological, social and behavioural hurdles to implementation of comparative effectiveness analyses and explain why these obstacles should not be ignored...
  33. ncbi request reprint Estimating the cost-effectiveness of 54 weeks of infliximab for rheumatoid arthritis
    John B Wong
    Division of Clinical Decision Making, Department of Medicine, Tupper Research Institute, Tufts New England Medical Center, Tufts University School of Medicine, Boston, Massachusetts 02111, USA
    Am J Med 113:400-8. 2002
    ..To estimate the cost-effectiveness of infliximab plus methotrexate for active, refractory rheumatoid arthritis...
  34. ncbi request reprint Estimating hip fracture morbidity, mortality and costs
    R Scott Braithwaite
    Section of Decision Sciences and Clinical Systems Modeling, Division of General Internal Medicine, Department of Medicine, University of Pittsburgh School of Medicine, 200 Lothrop Street, Pittsburgh, PA 15213, USA
    J Am Geriatr Soc 51:364-70. 2003
    ..To estimate lifetime morbidity, mortality, and costs from hip fracture incorporating the effect of deficits in activities of daily living...
  35. ncbi request reprint The cost effectiveness of infliximab for severe treatment-resistant rheumatoid arthritis in the UK
    Marco Barbieri
    Universitat Pompeu Fabra, Barcelona, Spain
    Pharmacoeconomics 23:607-18. 2005
    ....
  36. ncbi request reprint Economic evaluation of programs or interventions in the management of rheumatoid arthritis: defining a consensus-based reference case
    Andreas Maetzel
    Division of Clinical Decision Making and Health Care Research, Toronto General Research Institute, University Health Network, Toronto, Ontario, Canada
    J Rheumatol 30:891-6. 2003
    ..We provide the rationale for each element and discuss how each element has been addressed in published economic evaluations of DMARD...
  37. ncbi request reprint Comparing the public health burden of chronic hepatitis C and HIV infection in France
    Sylvie Deuffic-Burban
    Unité de Recherche Epidémiologie et Sciences de l Information INSERM U444, Faculte de Medecine Saint Antoine, 27 rue Chaligny, 75 571 Paris Cedex 12, France
    J Hepatol 40:319-26. 2004
    ..Using reported public health data in France and natural history models, we applied the back-calculation method to project future mortality from HCV and HIV incorporating current therapies...
  38. ncbi request reprint Strategies for managing anemia in hepatitis C patients undergoing antiviral therapy
    John G McHutchison
    Duke Clinical Research Institute, Division of Gastroenterology Duke University, Durham, North Carolina 27705, USA
    Am J Gastroenterol 102:880-9. 2007
    ..In the meantime, physicians must make the best possible use of the available options for managing anemia, especially in select patient groups who are most at risk for anemia and its complications...
  39. ncbi request reprint Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C
    Gary L Davis
    Division of Hepatology, Baylor University Medical Center, Dallas, TX 75246, USA
    Hepatology 38:645-52. 2003
    ..Patients who fail to achieve EVR will not clear virus even if an additional 9 months of therapy is received. Therapy can be confidently discontinued in those cases...
  40. ncbi request reprint Estimating the prognosis of hepatitis C patients infected by transfusion in Canada between 1986 and 1990
    Murray Krahn
    Toronto General Hospital, ES9 408, 200 Elizabeth Street, Toronto, Ontario M5G 2C4, Canada
    Med Decis Making 24:20-9. 2004
    ..To develop a natural history model for chronic hepatitis C virus (HCV) infection to determine allocation of compensatory funds to Canadians who acquired HCV through the blood supply from 1986 through 1990...
  41. ncbi request reprint Presidential reflections on the 25th anniversary of the society for medical decision making
    Arthur S Elstein
    Department of Medical Education, University of Illinois at Chicago, USA
    Med Decis Making 24:408-20. 2004
  42. ncbi request reprint Intermittent claudication: cost-effectiveness of revascularization versus exercise therapy
    Sybolt O de Vries
    Department of Health Sciences, University of Groningen, The Netherlands
    Radiology 222:25-36. 2002
    ..To compare the costs, effectiveness, and cost-effectiveness of alternative treatment strategies for intermittent claudication...
  43. ncbi request reprint Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025
    Russel Burge
    Procter and Gamble Pharmaceuticals and Personal Health, Mason, OH, USA
    J Bone Miner Res 22:465-75. 2007
    ..Total fractures were >2 million, costing nearly $17 billion in 2005. Men account for >25% of the burden. Rapid growth in the disease burden is projected among nonwhite populations...
  44. ncbi request reprint Estimating the proportion of patients infected with HIV who will die of comorbid diseases
    R Scott Braithwaite
    VAMC New Haven and Yale University School of Medicine, New Haven, Conn, USA
    Am J Med 118:890-8. 2005
    ..Effective antiretroviral therapies have improved the prognosis for patients infected with the human immunodeficiency virus (HIV). We aimed to estimate the likelihood that HIV-infected patients would die of comorbid disease...